OCTOBER 7, 2025 — 137 IN MASSACHUSETTS
The company announced a strategic portfolio prioritization, ending development of its cell therapy assets, including its gamma-delta T-cell therapy platform, as it seeks an external partner to take on its platform technologies and clinic-ready programs.
The product realignment will impact 137 of its Massachusetts employees.
According to a company spokesperson, “As part of a strategic portfolio prioritization, we have made the decision to discontinue our cell therapy efforts,” the company said in a statement. This will enable us to focus on areas with the greatest potential to deliver transformative therapies to patients with increased speed and scale. We will seek an external partner to leverage our cell therapy platform technologies and further advance our research and clinic-ready programs in this field.”
JULY 2, 2024 — 220 MORE EMPLOYEES TO FACE LAYOFFS
The restructuring continues as the company announced further job cuts that will impact 189 employees at its Cambridge headquarters and 31 at its Lexington site and occur between August 2024 and March 2025.
MAY 30, 2024 — 641 EMPLOYEES TARGETED IN MASSACHUSETTS
Continuing with its multiyear “efficiency program, the company is planning to lay off 641 employees, including 495 EMPLOYEES from its U.S. headquarters in Cambridge, Massachusetts, and 146 from its Lexington, Massachusetts facility.
The Board of Directors approved a significant multi-year program focused on organizational agility, spending efficiencies, and leveraging the company’s capabilities in data, digital, and technology (DD&T). The program aims to improve growth through continued advancement of Takeda’s Growth & Launch Products and progressing the company’s robust late-stage pipeline to deliver innovative therapies for patients while helping drive Core Operating Profit margin improvement target of low- to mid-30%.
The program will start in FY2024 and includes initiatives to optimize its workforce—simplifying some division structures—and rigorously prioritize its R&D pipeline while investing in DD&T to increase productivity and efficiency across the organization. Procurement-led initiatives will be centered on optimizing external spend with the goal of achieving cost savings and efficiencies in Takeda's supply chain and vendor management processes. Details and timing of specific actions within the framework of these broader initiatives will be decided in due course.”
MAY 30, 2023 — Original post…
Cambridge, Massachusetts-based Takeda Pharmaceutical Company, has announced that it will be stopping its early-stage programs in gene therapy, as well as rare blood diseases, to concentrate its resources on drugs that are closer to commercialization, including a midstage psoriasis drug that it bought from Nimbus Therapeutics.
The reduction in force will impact 186 employees, including research associates, research scientists, and clinical operations teams in four Cambridge, Massachusetts facilities, beginning in July 2023, and potentially taking place through March 2024.
Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something bad hasn't happened yet, doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?